Chromadex Corp Stock OTC Bulletin Board
Stocks
CDXC
US1710771007
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 242M 209M 196M 179M 337M 23.07B 342M 2.29B 900M 11.54B 908M 888M 38.43B | P/E 2026 * |
22.8x | P/E 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 242M 209M 196M 179M 337M 23.07B 342M 2.29B 900M 11.54B 908M 888M 38.43B | EV / Sales 2026 * |
1.82x | EV / Sales 2027 * | 1.56x |
| Free-Float |
70.54% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Chromadex Corp
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Fried
CEO | Chief Executive Officer | 66 | 2018-05-31 |
Ozan Pamir
DFI | Director of Finance/CFO | 35 | 2024-10-20 |
Mona Rosene
CTO | Chief Tech/Sci/R&D Officer | - | 2020-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Jaksch
CHM | Chairman | 57 | 2018-06-21 |
Robert Fried
BRD | Director/Board Member | 66 | 2015-07-08 |
Steven Rubin
BRD | Director/Board Member | 65 | 2017-03-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.79% | +3.38% | +6.28% | +16.23% | 50.03B | |
| +0.89% | +13.44% | +491.34% | +594.30% | 44.36B | |
| +3.08% | +14.42% | +24.57% | +81.39% | 40.82B | |
| +1.38% | +3.70% | +34.54% | +9.11% | 39.83B | |
| +0.85% | +10.32% | +21.22% | +47.64% | 32.51B | |
| +0.08% | +5.00% | - | - | 16.85B | |
| +1.99% | +5.08% | +38.70% | +125.08% | 16.81B | |
| -0.34% | +1.45% | +5.37% | +21.22% | 14.05B | |
| +3.56% | +19.98% | +86.23% | +27.29% | 13.22B | |
| Average | +1.19% | +279.70% | +88.53% | +115.28% | 29.83B | |
| Weighted average by Cap. | +1.06% | +295.03% | +107.48% | +139.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 133M 115M 108M 98.45M 186M 12.7B 188M 1.26B 496M 6.35B 500M 489M 21.15B | 155M 134M 126M 115M 216M 14.81B 220M 1.47B 578M 7.41B 583M 570M 24.68B |
| Net income | 10.88M 9.42M 8.81M 8.05M 15.17M 1.04B 15.41M 103M 40.53M 519M 40.87M 39.98M 1.73B | 12.82M 11.1M 10.38M 9.48M 17.87M 1.22B 18.15M 122M 47.74M 612M 48.14M 47.09M 2.04B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- NAGE Stock
- CDXC Stock
Select your edition
All financial news and data tailored to specific country editions
